International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2520-2528 www.ijprajournal.com ISSN: 2456-4494

A Comprehensive Review of Pharmacovigilance: Present, Past, and Future Perspectives in Patient Safety

Prof.(Dr). Mohd. Wasiullah [1], Prof.(Dr.) Piyush Yadav[2], Assistant professor Mohit Vishwakarma[3], Lecturer Shivendra dubey[4*], Abhishek kumar yadav[5]

Date of Submission: 25-04-2025 Date of Acceptance: 05-05-2025

ABSTRACT –
Pharmacovigilance (PV) has become an essential pillar in ensuring patient safety, particularly in the post-marketing phase of drug development. Initially, PV focused largely on passive, spontaneous reporting of adverse drug reactions (ADRs), but it has grown into an interdisciplinary science that emphasizes risk prevention through systematic monitoring, data interpretation, and regulatory cooperation . The infamous thalidomide incident in the 1960s served as a wake-up call, prompting the formation of structured pharmacovigilance systems and the initiation of international oversight programs like the WHO's global drug monitoring network .Today, pharmacovigilance utilizes advanced technologies such as big data analytics, real-world data, and digitized health records to detect safety concerns more efficiently. Agencies including the U.S. FDA and European Medicines Agency have implemented mechanisms like risk management plans (RMPs) and periodic safety update reports (PSURs), marking a shift from traditional passive models to proactive, continuous monitoring frameworks . These innovations improve the identification of rare or delayed adverse effects, thus elevating patient protection.Nevertheless, significant obstacles persist—among them, inconsistent ADR reporting, fragmented data sources, and underdeveloped pharmacovigilance systems in many lower-income nations. Addressing these issues demands enhanced global partnerships, training, and the inclusion of patient voices in the safety process . Emerging tools such as pharmacogenomics and artificial intelligence (AI) are reshaping PV, offering the potential to personalize treatment and predict individual risk before adverse events occur .In the years ahead, PV is expected to expand through decentralized clinical research, wearable technologies, and patient-generated data. This movement toward real-time and patient-centered safety assessment must be accompanied by strong data protection protocols and harmonized regulatory standards. To keep pace with evolving healthcare systems, sustained investment in PV infrastructure, education, and international cooperation will be vital for safeguarding public health .

Keywords Pharmacovigilance Evolution Drug Safety Monitoring Adverse Drug Reactions (ADR) Regulatory Frameworks Post-Marketing Surveillance

I. INTRODUCTION –

Pharmacovigilance (PV)—the scientific field and set of practices concerned with identifying, evaluating, comprehending, and preventing adverse effects and other drug-related complications—is a vital component of both patient safety and public health. Since the World Health Organization (WHO) formally established PV in 1968, it has evolved from a reactive, report-based system to a dynamic, multi-stakeholder discipline that includes regulatory bodies, pharmaceutical companies, healthcare professionals, and patients . The thalidomide disaster of the 1960s was a major turning point, highlighting the critical need for strong drug safety monitoring systems and marking a foundational moment in PV history .Traditionally, pharmacovigilance developed in response to medical crises, rather than through proactive planning. By the late 20th century, many nations had set up their own PV centers, while international cooperation—such as through the Uppsala Monitoring Centre (UMC)—enabled global sharing of safety data and detection of emerging risks . Still, spontaneous reporting systems face major limitations, particularly due to underreporting and inconsistent data quality. Research shows that only 6–10% of adverse drug reactions (ADRs) are actually reported, which makes early identification of risks more difficult .In more recent years, advances in technology and regulatory updates have reshaped PV into a more forward-looking and analytical field. The use of electronic health records (EHRs), big data tools, and artificial intelligence (AI) has allowed for faster signal detection and improved evaluations of cause and effect . Programs like the FDA's Sentinel Initiative and the European Medicines Agency's EudraVigilance have broadened PV efforts beyond clinical trials, incorporating real-world data to monitor drug safety on a larger scale . These systems rely on vast healthcare databases to identify safety concerns more rapidly and across diverse populations.Despite progress, significant hurdles persist, especially in low- and middle-income countries (LMICs), where PV systems are often incomplete or lack the necessary support. Issues such as insufficient funding, a shortage of trained professionals, and weak regulatory oversight make it difficult to implement effective PV practices. Given the global nature of drug distribution, harmonized regulations and compatible reporting platforms are essential to ensure drug safety across borders. Initiatives like the WHO Programme for International Drug Monitoring work to enhance global collaboration and build stronger international PV networks . Pharmacovigilance (PV) plays a crucial role in maintaining the safety and effectiveness of medications by identifying, evaluating, comprehending, and preventing adverse effects and other drug-related complications. As treatment strategies become more complex and pharmaceutical markets continue to expand globally, PV has become a vital component of public health frameworks. According to the World Health Organization (WHO), pharmacovigilance is defined as "the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem" . Over time, the purpose of PV has expanded beyond the identification of adverse drug reactions (ADRs) to include issues such as medication errors, drug interactions, and the long-term safety of drugs following their approval.The thalidomide disaster in the late 1950s and early 1960s was a major turning point in drug safety regulations.

Currently, pharmacovigilance is undergoing rapid evolution, fueled by advancements in technology, changes in regulation, and the active engagement of diverse stakeholders. Tools like electronic health records, big data analytics, and artificial intelligence (AI) are transforming how safety signals are detected and risks are evaluated . Additionally, digital technologies and social media have empowered patients to report ADRs directly and promptly, promoting a more patient-centric surveillance system . Regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have embraced more anticipatory and integrated risk management approaches, embedding PV practices throughout a drug's lifecycle .

Looking to the future, pharmacovigilance is expected to become increasingly predictive, personalized, and cohesive. Emerging technologies like pharmacogenomics, machine learning, and global data harmonization are aimed at improving the accuracy of safety predictions and facilitating early identification of potential drug hazards . Nevertheless, these advancements also introduce new challenges, such as concerns over data privacy, system interoperability, and the need for specialized training among healthcare professionals . As innovative treatments like gene therapies and personalized medicine continue to gain traction, PV systems will need to evolve to effectively monitor these novel and complex safety profiles.

Historical Overview of Pharmacovigilance -

1. Early Beginnings and the Foundation of Drug Safety Monitoring -

Pharmacovigilance, the discipline concerned with the detection, evaluation, comprehension, and prevention of adverse effects and other drug-related complications, traces its conceptual origins to the early 20th century. However, organized and systematic approaches to drug safety only began to emerge in response to significant public health incidents that exposed the dangers of unregulated drug use.

Initial regulatory measures, such as the U.S. Pure Food and Drug Act of 1906, aimed to address drug adulteration and mislabeling. These early laws focused more on drug quality control than on safety per se.

A turning point came In 1937, when a formulation of sulfanilamide using a toxic solvent led to the deaths of more than 100 people in the United States. This tragedy resulted in the passage of the 1938 Federal Food, Drug, and Cosmetic Act, which required pharmaceutical companies to demonstrate a drug's safety before it could be sold—marking one of the earliest formal safety requirements.

After World War II, the rapid growth in pharmaceutical innovation, combined with aging populations and increased polypharmacy, highlighted the need for ongoing safety monitoring beyond pre-approval testing, giving rise to pharmacovigilance as a specialized field.

2. Major Milestones: Thalidomide, Vioxx, and Regulatory Evolution

A. Thalidomide Crisis (1957–1961)

The thalidomide episode stands as one of the most pivotal events in drug safety history. Promoted in the late 1950s for treating morning sickness in pregnant women, thalidomide led to severe congenital deformities in over 10,000 babies worldwide. This event underscored serious deficiencies in regulatory oversight and sparked global reforms in drug approval and monitoring.

As a response, countries such as the U.S. and UK overhauled their drug regulation systems. The United States introduced the Kefauver-Harris Amendment in 1962, making it mandatory for drugs to be proven effective and safe before approval. The UK initiated the Yellow Card Scheme in 1964 to encourage healthcare professionals to report adverse drug reactions.

B. Vioxx Withdrawal (1999–2004)

Another significant event was the market withdrawal of Vioxx (rofecoxib), a painkiller, following the discovery of its link to elevated cardiovascular risks. Despite its widespread use since 1999, it was only after extensive post-marketing studies that the dangers became apparent. Merck removed the drug from the market in 2004, but not before tens of thousands of heart attacks were attributed to its use in the U.S. alone.

This case reinvigorated discussions on drug safety, transparency in clinical research, and the ethical responsibilities of pharmaceutical companies. It also prompted the FDA to launch the Sentinel Initiative and enforce stricter safety monitoring practices.

C. Broader Regulatory Developments

In Europe, pharmacovigilance gained momentum through the efforts of the European Medicines Agency (EMA). Key legislative developments such as Directive 2001/83/EC and Directive 2010/84/EU formalized centralized ADR reporting and laid the groundwork for systematic risk management strategies across EU member states.

3. Evolving Roles of Key Stakeholders in Drug Safety

A. Regulatory Agencies

Agencies such as the FDA (USA), EMA (Europe), MHRA (UK), and WHO have been instrumental in shaping and enforcing pharmacovigilance practices. Their responsibilities now extend beyond drug approval to include continuous oversight, manufacturer audits, and public safety communication.

The WHO's establishment of the Programme for International Drug Monitoring (PIDM) in 1968 marked a significant step toward global coordination in pharmacovigilance, with the VigiBase database serving as a global repository for individual case safety reports (ICSRs).

B.Healthcare Professionals

Doctors, pharmacists, and other medical personnel have traditionally been the primary sources of adverse event reporting. Although underreporting remains a challenge, increased awareness and technological support have improved their participation in safety monitoring. Their frontline experience remains critical for evaluating the real-world impact of medicines.

C. Regulatory bodies

Drug manufacturers are legally obligated to maintain pharmacovigilance systems, submit regular safety updates, and implement risk mitigation strategies. However, their involvement has at times been controversial, particularly when commercial interests conflict with transparency.

Regulatory bodies now enforce stricter oversight to ensure that pharmaceutical companies not only collect but also disclose safety information in a timely and accurate manner.

Current Practices in Pharmacovigilance

Pharmacovigilance (PV) is the scientific and operational discipline focused on identifying, evaluating, understanding, and preventing adverse effects or any drug-related complications. As therapeutic agents grow more complex and global drug usage increases, PV systems and strategies have evolved significantly. This review delves into the

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2520-2528 www.ijprajournal.com ISSN: 2456-4494

current global PV practices, emphasizing surveillance systems, methodologies, regulatory structures, technological advancements, and ongoing challenges shaping this vital healthcare field.

1. Overview of Pharmacovigilance Systems

Pharmacovigilance operates across global, national, and regional platforms to ensure drug safety by identifying and addressing risks in a timely manner.

FDA MedWatch (USA)

The U.S. FDA's MedWatch program encourages voluntary reporting of serious adverse events (AEs), product defects, and medication errors by healthcare providers and consumers. The data collected supports the FDA Adverse Event Reporting System (FAERS), which enables ongoing signal detection and regulatory actions. MedWatch has led to various label modifications and product withdrawals.

WHO VigiBase

VigiBase, administered by the Uppsala Monitoring Centre for the WHO, is the largest global database for Individual Case Safety Reports (ICSRs), collecting data from more than 130 member countries. It supports international signal detection through platforms such as VigiFlow (data management) and VigiLyze (signal analysis).

National and Regional Programs

Countries like the UK (Yellow Card Scheme), Canada (Canada Vigilance), India (PvPI), and those in the EU (EudraVigilance) operate comprehensive PV frameworks under local regulations. These systems work collaboratively with WHO initiatives and employ a combination of spontaneous reporting, EHRs, and active surveillance.

1. Challenges in Pharmacovigilance

Despite advancements, pharmacovigilance still encounters several challenges:
Low Reporting Rates
Only 1–10% of adverse drug reactions (ADRs) are reported, primarily due to:
Lack of awareness or training
Time constraints in clinical settings
Uncertainty in establishing causality
Efforts like integrating ADR reporting into EHRs and offering incentives are under trial.

Incomplete Data

Many ICSRs lack crucial details such as dosage, timing, and patient history. Enhancing training and standardizing report formats can improve data quality.
Engaging Healthcare Providers
Clinician participation is crucial but often hindered by:
Minimal feedback post-reporting
PV not being part of routine medical education
Variations in cultural and legal norms across regions
Innovations such as simplified reporting apps, anonymization, and feedback mechanisms are being explored to increase engagement.

2. Regulatory Systems and Oversight

Regulatory bodies enforce strict PV standards across the drug lifecycle:
The International Conference on Harmonisation (ICH) offers unified guidelines (e.g., ICH E2E) for PV planning
The European Medicines Agency (EMA) enforces Good Pharmacovigilance Practices (GVPs)
The FDA mandates REMS and post-market monitoring for high-risk medications
National authorities often adapt global guidelines to regional needs, blending WHO directives with local strategies

3. Role of Technology in Pharmacovigilance

Technological innovation is transforming PV through automation, integration, and enhanced data analytics.

Safety Databases

Systems like FAERS, EudraVigilance, VigiBase, and the Canada Vigilance Database house millions of ICSRs for global monitoring and trend analysis.

Digital Reporting Platforms

Online portals (e.g., MedWatch Online, Yellow Card app) allow clinicians and patients to report ADRs directly. Mobile technologies and AI-powered chatbots enhance accessibility and user engagement.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2520-2528 www.ijprajournal.com ISSN: 2456-4494

Artificial Intelligence (AI) and Natural Language Processing (NLP)

AI tools handle unstructured inputs from EHRs and social media, streamline ICSR processing, automate triage, and help prioritize potential safety issues. Predictive modeling is also emerging to flag high-risk products pre-market.

EHRs and Real-World Data (RWD)

Integrating PV into EHRs allows real-time tracking and data mining. RWD supports long-term studies and validation of safety signals in real-world settings.

Case Studies in Pharmacovigilance -

Pharmacovigilance (PV) involves the ongoing monitoring, evaluation, and prevention of adverse effects or other problems related to medicinal products. Through detailed case studies, we gain essential perspectives on how safety concerns are detected, the regulatory responses they prompt, and the long-term impact on healthcare policy. This review delves into significant historical safety incidents, showcases contemporary PV practices through real-world examples, and explores how such experiences shape evolving PV strategies and regulatory frameworks.

1. **Historical Drug Safety Events and Their Impact on Regulation**

Over the decades, several pivotal drug-related safety events have played a key role in transforming the pharmacovigilance landscape. These landmark cases highlighted the urgent need for structured and preventive safety oversight.

The Thalidomide Crisis (1957–1961)

Thalidomide was initially introduced as a sedative and anti-nausea medication for pregnant women. Unfortunately, it led to thousands of birth defects, particularly limb malformations.

Consequences:

Introduction of formal adverse event reporting systems (e.g., the UK's Yellow Card Scheme in 1964).

Implementation of stringent preclinical testing and post-market monitoring requirements.

Major reforms in drug approval protocols worldwide (e.g., Kefauver-Harris Amendments by the US FDA in 1962).

Rofecoxib (Vioxx) Controversy (1999–2004)

Marketed for managing arthritis and pain, Vioxx was later associated with a heightened risk of cardiovascular events, prompting its removal from the market.

Regulatory Outcomes:

Voluntary withdrawal in 2004 due to safety concerns.

Increased focus on comprehensive Risk Management Plans (RMPs).

Strengthened reliance on post-marketing data and real-world evidence in safety evaluations.

Benfluorex (Mediator) Incident (1976–2009)

Originally prescribed for diabetes, Benfluorex was also used off-label for weight loss. Over time, it was linked to severe heart valve damage.

Outcomes and Reform:

Catalyzed significant regulatory changes within the French healthcare system.

Led to the creation of the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) to enhance oversight at the European level.

2. **Modern-Day Pharmacovigilance in Action: Case Illustrations**

Contemporary PV practices emphasize proactive monitoring, technology-driven data analysis, and swift regulatory interventions. The following examples illustrate current methodologies in pharmacovigilance.

a. COVID-19 Vaccine Monitoring (2020–Present)

The global rollout of COVID-19 vaccines required unprecedented surveillance to ensure safety at scale.

b. Olaparib (Lynparza) and Use of Real-World Evidence

This PARP inhibitor, approved for ovarian cancer, demonstrated how real-world data can complement clinical trials in refining safety profiles.

Outcomes -

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2520-2528 www.ijprajournal.com ISSN: 2456-4494

Adjustments to dosing protocols and updates to safety warnings.
Improved patient safety through data-driven therapeutic adjustments.

3. Integrating Past Lessons into Future Pharmacovigilance Policies

Experience from previous drug safety incidents continues to inform and enhance PV strategies. This ongoing evolution involves regulatory innovation, stakeholder engagement, and advanced technologies.

Proactive Risk Management
Following earlier safety failures, RMPs are now a standard component of new drug applications. These plans typically include:
Specific risk mitigation strategies (e.g., restricted prescribing programs).
Regular submission of Periodic Safety Update Reports (PSURs).
Post-approval studies to further evaluate risk-benefit profiles (PASS).

Patient-Centered Reporting
Modern PV recognizes the value of patient input:
Many health authorities accept adverse event reports directly from patients.

Future Directions and Innovations in Pharmacovigilance-

Pharmacovigilance (PV) is rapidly evolving, driven by progress in digital technologies, data analytics, and regulatory advancements. This section outlines key innovations poised to transform the way drug safety is monitored and managed.

3.1 Technological Advancements in Pharmacovigilance

The adoption of cutting-edge technologies such as artificial intelligence (AI), machine learning (ML), big data tools, and natural language processing (NLP) is reshaping conventional PV practices.

AI and ML systems can now identify trends within massive datasets, allowing for quicker recognition of adverse drug reactions (ADRs). Automated tools for signal detection and case prioritization help streamline operations and enhance accuracy.

Big data tools enable the analysis of diverse information sources, including clinical trial data, social media activity, mobile health applications, and spontaneous reporting. These tools support real-time monitoring and help uncover complex drug-event interactions.

NLP boosts the ability to interpret unstructured content—such as doctor's notes, patient testimonials, and online discussions—for potential ADR signals that might be missed in traditional reports.
Together, these innovations increase the speed, scope, and effectiveness of pharmacovigilance systems.

3.2 Use of Electronic Health Records (EHRs) and Real-Time Monitoring

The increasing reliance on electronic health records provides a holistic view of individual patient histories, enhancing the understanding of drug exposure and clinical outcomes.

HER systems enable continuous and immediate monitoring of medication safety during routine healthcare delivery.

This approach allows for deeper insights into drug effects across varied population groups and health conditions.

Several nations, including the United States and members of the European Union, are implementing systems that link HER data to national pharmacovigilance infrastructures to support automated risk signal identification.

3.3 Early Risk Identification Through Predictive Analytics

Predictive analytics applies both historical and current data to foresee safety risks before they escalate.

Using statistical and machine learning models, these tools can pinpoint high-risk patient groups, anticipate potential ADRs, and assist in preemptive safety measures.

Such capabilities are particularly valuable in designing risk reduction strategies and conducting post-marketing surveillance, leading to quicker responses to emerging threats.

Machine learning techniques—both supervised and unsupervised—enhance these predictions and inform better regulatory and clinical choices.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2520-2528 www.ijprajournal.com ISSN: 2456-4494

3.4 Tailored Medicine and Genetic Factors in Drug Safety

Pharmacogenomics plays a crucial role in shaping personalized treatment strategies and minimizing adverse effects.

Genetic differences influence how individuals respond to medications, affecting both therapeutic outcomes and susceptibility to ADRs.

Incorporating genomic data into PV systems helps identify patients with a genetic predisposition to negative drug responses.

Nonetheless, barriers include the intricate nature of genetic data, privacy considerations, and the need for globally harmonized standards for genomic data integration in pharmacovigilance.

3.5 Evolving Regulations and International Collaboration

Regulatory bodies are adapting to technological advancements by revising existing policies and fostering global cooperation.

Organizations such as the EMA, FDA, and PMDA are investing in pilot projects involving AI, updating regulatory frameworks, and creating partnerships to support digital PV initiatives.

Global harmonization efforts, like ICH E19 and WHO's Vigibase, aim to standardize data collection and facilitate cross-border information exchange.

These developments enable more unified and effective pharmacovigilance processes worldwide, especially in the context of global drug development.

3.6 Ethical and Operational Challenges in Tech-Driven Pharmacovigilance

The rise of AI and digital platforms in pharmacovigilance introduces several ethical and logistical challenges:

Privacy and consent: The widespread use of sensitive data from EHRs and genetic testing necessitates strict adherence to privacy laws, including GDPR.

Bias in algorithms: AI systems must be thoroughly tested on diverse datasets to prevent biased results and ensure fair safety monitoring.

Transparency: Regulatory agencies demand that AI-generated decisions be understandable, traceable, and subject to audit.

Establishing robust human oversight, transparent governance, and responsible AI practices is critical to maintaining public confidence in these evolving systems.

Role of Stakeholders in Pharmacovigilance -

Pharmacovigilance plays a vital role in maintaining drug safety and efficacy within healthcare systems globally. It relies on the coordinated efforts of various stakeholders who are involved in identifying, documenting, and responding to adverse drug reactions (ADRs). These joint efforts contribute significantly to protecting patients and supporting regulatory decisions.

1. Regulatory Agencies: Supervision, Policy Development, and Compliance

Regulatory authorities are fundamental to pharmacovigilance. They create guidelines and enforce laws to protect public health. In India, the Central Drugs Standard Control Organization (CDSCO) manages the Pharmacovigilance Programme of India (PvPI), which gathers ADR data through a network of healthcare institutions. This data is analyzed to support decisions like modifying drug labels or removing unsafe medicines from the market.

Globally, organizations such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) work closely with national agencies and the World Health Organization (WHO). Their roles include standardizing ADR reporting methods, conducting safety assessments, and aligning pharmacovigilance protocols across different countries

2. Healthcare Professionals: Reporting ADRs and Promoting Patient Safety

Doctors, nurses, and pharmacists serve as the primary point of contact for patients and are key contributors to pharmacovigilance. They play an essential role in detecting and reporting ADRs. In India, healthcare workers submit ADRs using designated forms or through a dedicated helpline provided by PvPI .

In addition to reporting, healthcare professionals educate patients on drug-related risks, encourage proper use of medications, and stay informed through continuous training in pharmacovigilance. Their close interaction with patients enables early identification and management of adverse reactions.

2. **Pharmaceutical Companies: Ongoing Safety Monitoring and Information Sharing**

Drug manufacturers have a critical obligation to monitor the safety of their products throughout their lifecycle. This includes collecting ADR data, performing risk evaluations, and promptly sharing safety information with health authorities and professionals. They must regularly submit Periodic Safety Update Reports (PSURs) and immediately report any significant safety concerns.

Effective pharmacovigilance relies on close cooperation between the industry, regulators, and healthcare providers. By sharing their findings, pharmaceutical companies help build a deeper understanding of drug safety and support timely regulatory interventions.

II. CONCLUSION -

Pharmacovigilance has significantly progressed from its early days as a reactive system centered around spontaneous reporting of adverse drug reactions (ADRs). It has matured into a proactive, data-informed discipline that plays a critical role in healthcare and regulatory oversight. Historic drug safety tragedies, such as the thalidomide crisis, acted as catalysts for the establishment of formal pharmacovigilance systems, emphasizing the ongoing need for rigorous post-marketing surveillance and fostering international initiatives like the WHO Programme for International Drug Monitoring. Currently, pharmacovigilance incorporates sophisticated tools and technologies, including signal detection methods, real-world data analysis, and comprehensive risk management strategies. The integration of electronic medical records, big data technologies, and artificial intelligence has enhanced the accuracy and efficiency of identifying potential drug safety issues. Modern regulatory systems such as the European Union's Good Pharmacovigilance Practices (GVP) and the U.S. FDA's Risk Evaluation and Mitigation Strategies (REMS) ensure a structured approach to risk assessment and communication, reinforcing patient safety throughout the medication lifecycle. Looking to the future, the field is set to benefit from innovations in digital health, precision medicine, and enhanced global regulatory cooperation. Tools such as wearable health monitors, mobile apps, and social media analytics present opportunities for near real-time detection of adverse events and greater patient involvement. Furthermore, developments in genomics and pharmacogenomics will support more individualized safety assessments, contributing to the rise of precision pharmacovigilance

REFERENCES -

[1]. Edwards, I. R., & Aronson, J. K. (2000). Adverse drug reactions: definitions, diagnosis, and management. The Lancet, 356(9237), 1255–1259.
[2]. Uppsala Monitoring Centre. (2022). The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products. World Health Organization.
[3]. U.S. Food and Drug Administration (FDA). (2020). FDA Adverse Event Reporting System (FAERS).
[4]. Olsson, S., Pal, S. N., Stergachis, A., &Couper, M. (2010). Pharmacovigilance activities in 55 low- and middle-income countries. Drug Safety, 33(8), 689–703.
[5]. Wang, Q., Chen, R., & Xu, H. (2021). Artificial intelligence in pharmacovigilance: A perspective on the opportunities and challenges. Drug Safety, 44(6), 547–558.
[6]. Bate, A., & Evans, S. J. W. (2009). Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiology and Drug Safety, 18(6), 427–436.
[7]. World Health Organization. (2002). The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products. Geneva: WHO.
[8]. McBride, W. G. (1961). Thalidomide and congenital abnormalities. The Lancet, 278(7216), 1358.
[9]. Edwards, I. R., & Aronson, J. K. (2000). Adverse drug reactions: definitions, diagnosis, and management. The Lancet, 356(9237), 1255–1259.
[10]. Hazell, L., &Shakir, S. A. W. (2006). Under-reporting of adverse drug reactions: a systematic review. Drug Safety, 29(5), 385–396.
[11]. Harper, B., & Mousavi, S. (2020). Artificial intelligence and real-world data in

pharmacovigilance: What is the future? Clinical Pharmacology & Therapeutics, 108(2), 306–313.
[12]. Platt, R., Wilson, M., Chan, K. A., Benner, J. S., Marchibroda, J., & McClellan, M. (2018). The new Sentinel Network—Improving the evidence of medical-product safety. New England Journal of Medicine, 364(6), 498–499.
[13]. Aagaard, L., Strandell, J., Melskens, L., Petersen, P. S., &Holme Hansen, E. (2012). Global patterns of adverse drug reactions over a decade: Analyses of spontaneous reports to VigiBase. Drug Safety, 35(12), 1171–1182.
[14]. World Health Organization. (2015). WHO Pharmacovigilance Indicators: A Practical Manual for the Assessment of Pharmacovigilance Systems. Geneva: WHO.
[15]. Golder, S., Norman, G., &Loke, Y. K. (2015). Systematic review on the prevalence, frequency, and comparative value of adverse events data in social media. British Journal of Clinical Pharmacology, 80(4), 878–888
[16]. Wang, Y., & Strong, D. M. (2021). Ethics in pharmacovigilance: Balancing innovation and patient safety in the age of big data. Journal of Medical Ethics, 47(1), 57–62.
[17]. World Health Organization. (2002). The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products.
[18]. Kim JH, Scialli AR. Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci. 2011.
[19]. WHO Programme for International Drug Monitoring.